Filtered By:
Source: The American Journal of Cardiology
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 715 results found since Jan 2013.
Prediction of Incident Atrial Fibrillation According to Gender in Patients with Ischemic Stroke From a Nationwide Cohort
The CHA2DS2-VASc score may identify patients at higher risk of atrial fibrillation (AF) following ischemic stroke (IS) among patients without known AF. We compared gender-related differences in items from CHA2DS2-VASc score and their relationship with AF occurrence after IS. This French cohort study was based on the database covering hospital care from 2009 to 2012 for the entire population. Of 336,291 patients with IS, 240,459 (71.5%) had no AF at baseline. Women were older, more frequently had hypertension, heart failure, and had a higher CHA2DS2-VASc score than men (4.63 vs 4.39, p
Source: The American Journal of Cardiology - November 30, 2017 Category: Cardiology Authors: Arnaud Bisson, Alexandre Bodin, Nicolas Clementy, Dominique Babuty, Gregory Y.H. Lip, Laurent Fauchier Source Type: research
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients with Atrial Fibrillation
The objective of the study was to examine how the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and warfarin differ across subgroups of atrial fibrillation (AF) patients defined by stroke risk (CHA2DS2-VASc score ≤3, 4-5, ≥6). Using claims data from a 5% random sample of Medicare beneficiaries, we identified patients newly diagnosed with AF in 2013-2014 who initiated warfarin (n=12,354), apixaban (n=2,358), dabigatran (n=1,415) or rivaroxaban (n=5,139), and categorized them according to their CHA2DS2-VAS c score (≤3, 4-5, ≥6).
Source: The American Journal of Cardiology - March 28, 2018 Category: Cardiology Authors: Inmaculada Hernandez, Yuting Zhang, Samir Saba Source Type: research
Usefulness of Proneurotensin to Predict Cardiovascular and All-Cause Mortality in a United States Population (From the REasons for Geographic and Racial Differences in Stroke Study)
Cardiovascular disease is a leading cause of death. Proneurotensin is a biomarker associated with the development of cardiovascular disease, cardiovascular mortality, and all-cause mortality. We assessed the association of fasting proneurotensin with mortal events by sex and race (black-white) in a United States (US) population. Using a case-cohort sub-population of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study, fasting proneurotensin was measured on a 1046-person subcohort and 651 participants with incident coronary heart disease (CHD).
Source: The American Journal of Cardiology - March 28, 2018 Category: Cardiology Authors: Nicholas Wettersten, Mary Cushman, Virginia J. Howard, Oliver Hartmann, Gerasimos Filippatos, Neil Beri, Paul Clopton, George Howard, Monika M. Safford, Suzanne E. Judd, Andreas Bergmann, Joachim Struck, Alan Maisel Source Type: research
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation
The objective of the study was to examine how the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and warfarin differ across subgroups of patients with atrial fibrillation defined by stroke risk (CHA2DS2-VASc score ≤3, 4 to 5, ≥6). Using Medicare claims data, we identified patients newly diagnosed with atrial fibrillation in 2013 to 2014 who initiated warfarin (n=12,354), apixaban (n=2,358), dabigatran (n=1,415), or rivaroxaban (n=5,139), and categorized them according to their CHA2DS2-VASc score (≤3, 4 to 5, ≥6).
Source: The American Journal of Cardiology - March 28, 2018 Category: Cardiology Authors: Inmaculada Hernandez, Yuting Zhang, Samir Saba Source Type: research
Usefulness of Proneurotensin to Predict Cardiovascular and All-Cause Mortality in a United States Population (From the REasons for Geographic and Racial Differences in Stroke Study)
Cardiovascular disease is a leading cause of death. Proneurotensin is a biomarker associated with the development of cardiovascular disease, cardiovascular mortality, and all-cause mortality. We assessed the association of fasting proneurotensin with mortal events by sex and race (black-white) in a United States (US) population. Using a case-cohort sub-population of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study, fasting proneurotensin was measured on a 1046-person subcohort and 651 participants with incident coronary heart disease (CHD).
Source: The American Journal of Cardiology - March 28, 2018 Category: Cardiology Authors: Nicholas Wettersten, Mary Cushman, Virginia J. Howard, Oliver Hartmann, Gerasimos Filippatos, Neil Beri, Paul Clopton, George Howard, Monika M. Safford, Suzanne E. Judd, Andreas Bergmann, Joachim Struck, Alan Maisel Source Type: research
Usefulness of the CHA2DS2-VASc and HAS-BLED Scores in Predicting the Risk of Stroke Versus Intracranial Bleeding in Patients With Atrial Fibrillation (from the FibStroke Study)
CHA2DS2-VASc and HAS-BLED scores stratify the risk of thromboembolic and bleeding events respectively in patients with atrial fibrillation. There is only little information on how they differentiate which of the 2 clinically most important complications (ischemic stroke [IS] or an intracranial bleeding [IB]) the patient is more prone to suffer. We evaluated both scores in patients with either of these major complications. The FibStroke Study collected data on all patients with atrial fibrillation with either an IS or an IB event between 2003 and 2012 in 4 Finnish hospital districts.
Source: The American Journal of Cardiology - February 12, 2018 Category: Cardiology Authors: Samuli Jaakkola, Tuomas O. Kiviniemi, Ilpo Nuotio, Juha Hartikainen, Pirjo Mustonen, Antti Palom äki, Jussi Jaakkola, Antti Ylitalo, Päivi Hartikainen, K.E. Juhani Airaksinen Source Type: research
Willingness to be Re-initiated on a Statin (From the REasons for Geographic And Racial Differences in Stroke REGARDS Study)
Guidelines recommend attempting to re-initiate statins in patients who discontinue treatment. Prior experiences while taking a statin, including side effects, may reduce a person's willingness to re-initiate treatment. We determined the percentage of adults who are willing to re-initiate statin therapy after treatment discontinuation. Factors associated with willingness to re-initiate a statin were also examined. A statin questionnaire was administered and study examination conducted among black and white US adults enrolled in the nationwide REasons for Geographic And Racial Differences in Stroke (REGARDS) study between 2013 and 2017.
Source: The American Journal of Cardiology - June 2, 2018 Category: Cardiology Authors: Matthew T. Mefford, Gabriel S. Tajeu, Rikki M. Tanner, Lisandro D. Colantonio, Keri L. Monda, Ricardo Dent, Michael E. Farkouh, Robert S. Rosenson, Monika M. Safford, Paul Muntner Source Type: research
Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study)
Guidelines recommend attempting to reinitiate statins in patients who discontinue treatment. Previous experiences while taking a statin, including side effects, may reduce a patient ’s willingness to reinitiate treatment. We determined the percentage of adults who are willing to reinitiate statin therapy after treatment discontinuation. Factors associated with willingness to reinitiate a statin were also examined. A statin questionnaire was administered and study examination conducted in black and white US adults enrolled in the nationwide REasons for Geographic And Racial Differences in Stroke study from 2013 to 2017.
Source: The American Journal of Cardiology - June 2, 2018 Category: Cardiology Authors: Matthew T. Mefford, Gabriel S. Tajeu, Rikki M. Tanner, Lisandro D. Colantonio, Keri L. Monda, Ricardo Dent, Michael E. Farkouh, Robert S. Rosenson, Monika M. Safford, Paul Muntner Source Type: research
Lifetime Pattern of Atrial Fibrillation and the Risks of Stroke and Death in a Population-based Cohort of Men (From The Manitoba Follow-Up Study)
Atrial Fibrillation (AF) is associated with stroke and mortality. The arrhythmia can be sustained or intermittent. Prior studies that have used fixed covariates and short time horizons to examine the relationship between the pattern of AF and the occurrence of events have produced conflicting results. The Manitoba Follow-Up Study includes 3983 originally healthy men who have been followed with routine examinations since 1948. AF status during each visit was classified into the following patterns: free of AF, newly-diagnosed; intermittent AF – in sinus; intermittent AF – in AF; sustained AF.
Source: The American Journal of Cardiology - August 20, 2018 Category: Cardiology Authors: William F. McIntyre, Philip D. St John, Mahmoud Torabi, Robert B. Tate Source Type: research
Relation of Race, Apparent Disability, and Stroke Risk With Warfarin Prescribing for Atrial Fibrillation in Patients Receiving Maintenance Hemodialysis
We examined patterns of warfarin use, and associated factors, after AF diagnosis. This retrospective cohort analysis studied US Medicare patients receiving maintenance dialysis January 1, 2008-June 30, 2010. Demographics, comorbidity, and a durable medical equipment claims-based disability proxy score predicted warfarin prescription after AF diagnosis. The analysis included 8964 patients with non-valvular AF.
Source: The American Journal of Cardiology - November 24, 2018 Category: Cardiology Authors: James B. Wetmore, Yi Peng, David T. Gilbertson, Jiannong Liu Source Type: research
Relation of Admission Blood Pressure to In-hospital and 90-Day Outcomes in Patients Presenting with Transient Ischemic Attack
The association between admission blood pressure (BP) and outcomes in patients with transient ischemic attack (TIA) is not well defined. Patients in the United States national Get With The Guidelines-Stroke registry with a TIA were included. Admission systolic and diastolic BP was used to compute mean arterial pressure (MAP) and pulse pressure (PP). A subset of this cohort was linked to CMS claims data for post-discharge outcomes. The in-hospital outcomes of interest were: mortality, not discharged home, and inability to ambulate independently at discharge.
Source: The American Journal of Cardiology - January 10, 2019 Category: Cardiology Authors: Sripal Bangalore, Lee Schwamm, Eric E. Smith, Anne S. Hellkamp, Ying Xian, Phillip J. Schulte, Jeffrey L. Saver, Gregg C. Fonarow, Deepak L. Bhatt, for the Get With The Guidelines-Stroke Steering Committee and Investigators Source Type: research
Thoracoscopic Left Atrial Appendage Occlusion for Stroke Prevention Compared with Long-Term Warfarin Therapy in Patients With Nonvalvular Atrial Fibrillation
In their recent paper, Fu et al. conclude that thoracoscopic left atrial appendage (LAA) occlusion is superior to warfarin for a composite outcome of stroke, systemic embolism and mortality.1 We suggest considering their results with caution.
Source: The American Journal of Cardiology - February 8, 2019 Category: Cardiology Authors: Sophie Weiwei Gao, Emilie Prudence Belley-C ôté, Kevin John Um, Richard Paul Whitlock Tags: Reader's Comments Source Type: research
Medication-taking Behaviors and Perceptions Among Adults with Heart Failure (From the REasons for Geographic And Racial Differences in Stroke REGARDS Study)
We examined medication-taking behaviors and perceptions among individuals with HF with a particular focus on BBs. A mailed survey on medication use was administered to US adults with HF enrolled in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.
Source: The American Journal of Cardiology - February 23, 2019 Category: Cardiology Authors: Matthew T. Mefford, Alysse Sephel, Melissa K. Van Dyke, Ligong Chen, Raegan W. Durant, Todd M. Brown, Matthew Fifolt, Juan Maya, Parag Goyal, Monika M. Safford, Emily B. Levitan Source Type: research
Stroke and Systemic Embolism and other Adverse Outcomes of Heart Failure with Preserved and Reduced Ejection Fraction in Patients with Atrial Fibrillation (From the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation CODE-AF)
It is unknown whether heart failure (HF) with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) carry a similar risk of stroke or systemic embolism (SE) and other outcomes in patients with non-valvular atrial fibrillation (AF). A prospective, multicenter outpatient registry with echocardiographic data which enrolled 10,589 patients from June 2016 to May 2019 was analyzed. In this registry, 935 (8.8%) patients had HF, and the proportions of patients with HFpEF and HFrEF were 43.2% and 56.8%, respectively.
Source: The American Journal of Cardiology - October 9, 2019 Category: Cardiology Authors: Seyong Chung, Tae-Hoon Kim, Jae-Sun Uhm, Myung-Jin Cha, Jung-Myung Lee, Junbeom Park, Jin-Kyu Park, Ki-Woon Kang, Jun Kim, Hyung Wook Park, Eue-Keun Choi, Jin-Bae Kim, Chang-Soo Kim, Young Soo Lee, Jaemin Shim, Boyoung Joung Source Type: research
Stroke Risk Based on CHA2DS2-VASc sScore in the Absence of Atrial Fibrillation
Ording et al. investigated the stroke risk in hospitalized individuals without atrial fibrillation (AF) and found it quite comparable to those with AF, especially in the setting of high (>5) CHA2DS2-VASc scores (13.3% vs. 14.6% in those without and with AF respectively).1 In fact, in men age5 without presence of AF, the risk of stoke was slightly higher than those with AF counterparts.
Source: The American Journal of Cardiology - November 27, 2019 Category: Cardiology Authors: Raj Nayyar, Dwijesh Sheth, Lovely Chhabra Source Type: research
